Market Place
Sourcing Support
BriaCell Validates Bria-OTS+™ Mechanism in Top Cancer Journal
26 Aug 2025 //
GLOBENEWSWIRE
BriaCell Secures $2M NCI Grant for Bria-PROS+™ in Prostate Cancer
25 Aug 2025 //
GLOBENEWSWIRE
BriaCell Sets Date for Share Consolidation Proposal
21 Aug 2025 //
GLOBENEWSWIRE
BriaCell Selected for MSK 2025 Cancer Accelerator Program
13 Aug 2025 //
GLOBENEWSWIRE
BriaCell Announces Proposed Effective Date of Share Consolidation
05 Aug 2025 //
GLOBENEWSWIRE
BriaCell Includes UCLA Health in Phase 3 Breast Cancer Study
31 Jul 2025 //
GLOBENEWSWIRE
BriaCell Receives New Zealand Patent for Whole Cell Tech
30 Jul 2025 //
GLOBENEWSWIRE
BriaPro Files Patent for Immuno-Oncology Multitargeting Agents
29 Jul 2025 //
GLOBENEWSWIRE
Bria Cell Presents Two Clinical Data Posters at ESMO 2025
25 Jul 2025 //
GLOBENEWSWIRE
BriaCell Therapeutics Closes $15M Public Offering
16 Jul 2025 //
GLOBENEWSWIRE
BriaCell Includes Mayo Clinic in Phase 3 Breast Cancer Study
15 Jul 2025 //
GLOBENEWSWIRE
BriaCell Announces $15M Public Offering Pricing
15 Jul 2025 //
GLOBENEWSWIRE
Bria-IMT Outperforms Trodelvy in Metastatic Breast Cancer
11 Jul 2025 //
GLOBENEWSWIRE
BriaCell Reports Full Brain Metastasis Resolution in Patient
10 Jul 2025 //
GLOBENEWSWIRE
BriaCell Patient Shows Complete Lung Metastasis Resolution Study
09 Jul 2025 //
GLOBENEWSWIRE
BriaCell: 52% Breast Cancer Patients Pass One-Year Mark
08 Jul 2025 //
GLOBENEWSWIRE
BriaCell Adds Phase 3 Sites in Los Angeles and Yale Hospital
02 Jul 2025 //
GLOBENEWSWIRE
BriaCell Gets DSMB Green Light for Ph 3 Breast Cancer Trial
24 Jun 2025 //
GLOBENEWSWIRE
BriaCell to Hold Virtual Investor Presentations on June 12 & 26
04 Jun 2025 //
GLOBENEWSWIRE
BriaCell Reports Strong Data at ASCO 2025
02 Jun 2025 //
GLOBENEWSWIRE
BriaCell Doses 1st Patient in Bria-OTS Ph1/2 Safety Study
27 May 2025 //
GLOBENEWSWIRE
BriaCell Abstracts Positive Data at ASCO 2025
23 May 2025 //
GLOBENEWSWIRE
BriaCell CEO Letter to Shareholders
20 May 2025 //
GLOBENEWSWIRE
BriaCell Reports Positive Phase 3 Data at AACR 2025
30 Apr 2025 //
GLOBENEWSWIRE
BriaCell Shows Survival and Clinical Benefit at AACR 2025
28 Apr 2025 //
GLOBENEWSWIRE
BriaCell Therapeutics Closes $13.8M Public Offering
28 Apr 2025 //
GLOBENEWSWIRE
BriaCell Therapeutics Prices $13.8M Public Offering
24 Apr 2025 //
GLOBENEWSWIRE
BriaCell Announces Four Clinical Data Presentations at ASCO 2025
23 Apr 2025 //
GLOBENEWSWIRE
BriaCell Ph 3 Study Enrollment Accelerating in (Bria-ABC) Cancer
22 Apr 2025 //
GLOBENEWSWIRE
BriaCell Phase 2 Data Beats Standard in HR+ Breast Cancer
16 Apr 2025 //
GLOBENEWSWIRE
BriaCell`s BriaPro Develops Antibodies for Cancer Target B7-H3
10 Apr 2025 //
GLOBENEWSWIRE
BriaCell to Present Data at 2025 AACR Conference
26 Mar 2025 //
GLOBENEWSWIRE
Second Board Recommends Continuing BriaCell’s Phase 3 Breast Cancer
20 Mar 2025 //
GLOBENEWSWIRE
BriaCell Therapeutics Announces Closing of Public Offering
05 Feb 2025 //
GLOBENEWSWIRE
BriaCell Therapeutics Corp Announces Result of Shareholder Meeting
05 Feb 2025 //
GLOBENEWSWIRE
BriaCell Therapeutics Announces Public Offering of Common Shares
03 Feb 2025 //
GLOBENEWSWIRE
BriaCell Therapeutics Announces Pricing of Public Offering
03 Feb 2025 //
GLOBENEWSWIRE
BriaCell Announces Resolution of Lung Metastasis in 1st Patient
03 Feb 2025 //
GLOBENEWSWIRE
BriaCell Announces Completion of 15:1 Share Consolidation
27 Jan 2025 //
GLOBENEWSWIRE
BriaCell Announces Proposed Effective Date of Share Consolidation
03 Jan 2025 //
GLOBENEWSWIRE
BriaCell Announces Rescheduling of Annual Meeting to Feb 5, 2025
03 Jan 2025 //
GLOBENEWSWIRE
BriaCell Announces AGM Materials & Voting Procedures Availability
17 Dec 2024 //
GLOBENEWSWIRE
BriaCell 2024 SABCS® Poster Highlights Bria-IMT™ Benefits
13 Dec 2024 //
GLOBENEWSWIRE
BriaCell Closes $5.5M Public Offering Successfully
13 Dec 2024 //
GLOBENEWSWIRE
BriaCell Presents Data in Metastatic Breast Cancer at SABCS
11 Dec 2024 //
GLOBENEWSWIRE
BriaCell Therapeutics Announces Proposed Public Offering
11 Dec 2024 //
GLOBENEWSWIRE
BriaCell Therapeutics Prices $5.5 Million Public Offering
11 Dec 2024 //
GLOBENEWSWIRE
BriaCell to Present SABCS® Spotlight Poster on Breast Cancer
26 Nov 2024 //
GLOBENEWSWIRE
BriaCell Provides Update to its Board of Directors
25 Nov 2024 //
GLOBENEWSWIRE
BriaCell Doses First Patient in Metastatic Breast Cancer Study
21 Nov 2024 //
GLOBENEWSWIRE
BriaCell Showcases Off-the-Shelf Immunotherapy at SITC 2024
08 Nov 2024 //
GLOBENEWSWIRE
BriaCell’s Overall Survival Data Selected for SABCS 2024 Spotlight
04 Nov 2024 //
GLOBENEWSWIRE
BriaCell Reports Survival Data For Metastatic Breast Cancer
22 Oct 2024 //
GLOBENEWSWIRE
BriaCell Provides Phase 3 Clinical Update In Metastatic Breast Cancer
15 Oct 2024 //
GLOBENEWSWIRE
BriaCell Therapeutics Announces Closing of $5 Million Offering
03 Oct 2024 //
GLOBENEWSWIRE
BriaCell Therapeutics Announces $5 Million Offering
01 Oct 2024 //
GLOBENEWSWIRE
BriaCell Announces FDA-Authorized Expanded Access Policy
18 Sep 2024 //
GLOBENEWSWIRE
BriaCell Therapeutics Announces Closing of $8.5 Million Offering
12 Sep 2024 //
GLOBENEWSWIRE
BriaCell Reports Positive Overall Survival (OS) in Metastatic Breast Cancer
11 Sep 2024 //
GLOBENEWSWIRE
BriaCell Therapeutics Announces $8.5 Million Offering
11 Sep 2024 //
GLOBENEWSWIRE
